Long-term prognosis and management of hepatocellular carcinoma after curative treatment

키워드

참고문헌 (20)

1. Kanwal F, "Surveillance for Hepatocellular carcinoma : current best practice and future direction", Gastroenterology, 157, pp.54~64 (2019)
2. Shiina S, "Radiofrequency ablation for hepatocellular carcinoma : 10-year outcome and prognostic factors", Am J Gastroenterol, 107, pp.569~577 (2012)
3. Nahon P, "Eradication of hepatitis c virus infection in patients with cirrhosis reduces risk of liver and non-liver complications", Gastroenterology, 152, pp.142~156.e2 (2017)
4. Jihye Kim, "Substantial risk of recurrence even after 5 recurrence-free years in early-stage hepatocellular carcinoma patients", Clinical and Molecular Hepatology, 26(4), pp.516~528 (2020), 대한간학회[DOI]
5. Nishida N, "Molecular scoring of hepatocellular carcinoma for predicting metastatic recurrence and requirements of systemic chemotherapy", Cancers(Basel), 10, pp.367~ (2018)
6. Nishida N, "Characteristic patterns of altered DNA methylation predict emergence of human hepatocellular carcinoma", Hepatology, 56, pp.994~1003 (2012)
7. Nishida N, "Hepatic DNA methylation is affected by hepatocellular carcinoma risk in patients with and without hepatitis virus", Dig Dis, 33, pp.745~750 (2015)
8. Nishida N, "Unique features associated with hepatic oxidative DNA damage and DNA methylation in non-alcoholic fatty liver disease", J Gastroenterol Hepatol, 31, pp.1646~1653 (2016)
9. Hughes DM, "Serum levels of α-fetoprotein increased more than 10years before detection of hepatocellular carcinoma", Clin Gastroenterol Hepatol (2020)[DOI]
10. Fujimoto A, "Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer", Nat Genet, 48, pp.500~509 (2016)
11. Liu J, "A viral exposure signature defines early onset of hepatocellular carcinoma", Cell, 182, pp.317~328.e10 (2020)[DOI]
12. Bruix J, "Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation(STORM) : a phase 3, randomised, double-blind, placebocontrolled trial", Lancet Oncol, 16, pp.1344~1354 (2015)
13. Yoshida H, "Effect of vitamin K2 on the recurrence of hepatocellular carcinoma", Hepatology, 54, pp.532~540 (2011)
14. Chen LT, "Long-term results of a randomized, observation-controlled, phase III trial of adjuvant interferon Alfa-2b in hepatocellular carcinoma after curative resection", Ann Surg, 255, pp.8~17 (2012)
15. Kim SK, "Comprehensive analysis of genetic aberrations linked to tumorigenesis in regenerative nodules of liver cirrhosis", J Gastroenterol, 54, pp.628~640 (2019)
16. Nishida N, "Molecular mechanism and prediction of sorafenib chemoresistance in human hepatocellular carcinoma", Dig Dis, 33, pp.771~779 (2015)
17. Nishida N, "Immune checkpoint blockade for the treatment of human hepatocellular carcinoma", Hepatol Res, 48, pp.622~634 (2018)
18. Nishida N, "Association between genetic and immunological background of hepatocellular carcinoma and expression of programmed cell death-1", Liver Cancer, 9, pp.426~439 (2020)
19. Nishida N, "Immune phenotype and immune checkpoint inhibitors for the treatment of human hepatocellular carcinoma", Cancers(Basel), 12, pp.1274~ (2020)
20. Brown ZJ, "Adjuvant treatment of hepatocellular carcinoma : prospect of immunotherapy", Hepatology, 70, pp.1437~1442 (2019)

관련 논문AI추천